MedTrace Logo

Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo

NCT00434967 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2207

Last updated 2010-12-16

Study results available
· View outcomes & findings →

Summary

The aim is to compare the blood pressure lowering effect of the combination of candesartan cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg to that of candesartan 32 mg alone, HCT 25 mg alone and placebo in hypertensive adults.

Conditions

Interventions

DRUG

Candesartan cilexetil

32 mg oral tablet

DRUG

Hydrochlorothiazide

25 mg oral tablet

DRUG

Candesartan/HCT 32/25 mg

Sponsors & Collaborators

Principal Investigators

  • Michael Klibaner, MD · AstraZeneca

  • Istvan Edes, MD · DEOEC Institute of Cardiology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • Belgium
  • Latvia
  • Malta
  • Romania
  • Russia
  • Slovakia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00434967 on ClinicalTrials.gov